|
Canada-0-LOCKSMITHS selskapets Kataloger
|
Firma Nyheter:
- UC Irvine Breast Cancer Clinical Trials — Orange County, CA
Breast Cancer clinical trials at UC Irvine 48 in progress, 20 open to eligible people -positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4 6 inhibitors (CDK4 6is) and endocrine therapy, either in the locally advanced
- Breast-Oncology Clinical Trials - University of California, Irvine
Locally advanced or metastatic HER2-positive or HER2-low (IHC1+ IHC2+, HER2-negative) breast cancer Must have progression during or after the most recent treatment for advanced metastatic cancer No prior treatment with anti-CD47 or SIRP-alpha agent If brain metastasis is present, disease must be stable
- Ph3StudyGedatolisib Combw Palbociclib Fulvestrant . . . - UCI Health
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+ HER2- breast cancer following progression on or after CDK4 6 and aromatase inhibitor therapy
- Treatment of Stage IV (Metastatic) Breast Cancer
Treatment for advanced breast cancer can often shrink the cancer or slow its growth (sometimes for many years), but after a time, it tends to stop working Further treatment options at this point depend on several factors, including previous treatments, where the cancer is located, a woman's menopause status, general health, desire to continue
- Arvinas and Pfizers Vepdegestrant Significantly Improves Progression . . .
The U S Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+ HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy About Arvinas
- Which Tx Combo Is Best for HER2+ Breast Cancer? - Medscape
The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for
- Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO . . .
The purpose of this guideline is to provide expert guidance on the systemic treatment of metastatic breast cancer (MBC) to clinicians, public health leaders, patients, and policymakers in resource-constrained settings If a patient's HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted
- UC Irvine Breast Cancer Trial: Disitamab Vedotin With Other Anticancer . . .
This is called advanced or metastatic cancer Participants in this study must have breast cancer or gastric cancer Participants must have tumors that have HER2 on them This allows the cancer to grow more quickly or spread faster There are few treatment options for patients with advanced or metastatic solid tumors that express HER2
- Liquid biopsies alert advanced breast cancer patients when new drugs . . .
New research suggests that blood tests known as “liquid biopsies” can improve the treatment of some people with metastatic breast cancer and help their tumors remain under control for more
- Breast Oncology - University of California, Irvine
UCI 22-09 A Phase Ib, First-In-Human, Dose Escalation and Expansion, Progression after or during the most recent systemic regimen of treatment for advanced cancer Exclusion: Males or females with relapsed refractory metastatic breast cancer (TNBC, or ER+ HER2-) must have progressed through at least 2 lines of therapy
|
|